Ivanoe Vega Dulanto, MD
Hematology & Oncology · Abilene, TXNPI 1992913461
Payments from drug & device makers
Across 183 payments — averaging $84.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$9K
- Bristol Myers Squibb$3K
- Novartis$406
- Pfizer$383
- Merck$367
- Johnson & Johnson$268
- plus $2K from 36 others
What the payments were for
- Food & beverage$3,23899%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 5 | $9,238 |
| Bristol Myers Squibb | 6 | $2,954 |
| Novartis | 20 | $406 |
| Pfizer | 31 | $383 |
| Merck | 16 | $367 |
| Johnson & Johnson | 13 | $268 |
| AstraZeneca | 10 | $233 |
| Eisai Inc. | 7 | $127 |
| Seagen Inc. | 8 | $127 |
| Sanofi | 7 | $120 |
| Gilead(2 entities) | 5 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Bayer | 5 | $79 |
| Intuitive Surgical | 1 | $76 |
| Astellas Pharma US Inc | 5 | $75 |
| Amgen | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $52 |
| Stemline Therapeutics Inc. | 2 | $40 |
| GSK | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $37 |
| Beone Medicines USA, Inc. | 2 | $34 |
| Legend Biotech USA Inc. | 1 | $34 |
| Rigel Pharmaceuticals, Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $31 |
| ADC Therapeutics America, Inc. | 1 | $30 |
| Pharmaessentia USA Corporation | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Exelixis Inc. | 1 | $27 |
| Geron Corporation | 1 | $26 |
| Tesaro, Inc. | 2 | $25 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Beigene USA, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $11 |
| Secura Bio, Inc. | 1 | $11 |
How this compares
$15,403 in reported general payments places this provider in the 55th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 44 | $675,400 |
| RevlimidLenalidomide | 36 | $533,652 |
| XtandiEnzalutamide | 34 | $508,678 |
| Abiraterone Acetate | 34 | $101,900 |
| EliquisApixaban | 20 | $13,177 |
| Anastrozole | 156 | $2,192 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $1,339 |
| Tamoxifen Citrate | 52 | $1,270 |
| Morphine Sulfate ErMorphine Sulfate | 34 | $1,082 |
| Ondansetron OdtOndansetron | 51 | $869 |
| Letrozole | 26 | $469 |
| Levothyroxine Sodium | 60 | $426 |
| Potassium Chloride | 49 | $345 |
| Imatinib Mesylate | 12 | $338 |
| Alendronate Sodium | 80 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $2,954 | $533,65236 claims |
| Astellas Pharma US IncXtandi | $75 | $508,67834 claims |
| PfizerEliquis | $383 | $13,17720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Abilene
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.